MeTA Assessment Toolbox


Published on

Presentation by Dennis Ross-Degnan on tools and approaches that can be used by countries involved in the Medicines Transparency Alliance (MeTA), at the London launch in May 2008

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • MeTA Assessment Toolbox

    1. 1. Dennis Ross-Degnan MeTA Tool Box 04/06/09
    2. 2. MeTA Goal and Strategy <ul><li>Goal: Equitable access to affordable essential medicines in order to improve health outcomes </li></ul><ul><li>Primary Objective 1: Increased transparency </li></ul><ul><ul><li>Disclosure and use of key pharmaceutical sector information </li></ul></ul><ul><ul><li>Quality, availability, affordability, access, and use </li></ul></ul><ul><li>Primary Objective 2: Multi-stakeholder alliance </li></ul><ul><ul><li>Support multi-stakeholder process </li></ul></ul><ul><ul><li>Strengthen governance and stakeholder accountability </li></ul></ul>
    3. 3. MeTA Country Activities During Pilot <ul><li>Develop and sustain national multi-stakeholder alliance and activities </li></ul><ul><li>Disclosure and use of key pharmaceutical data </li></ul><ul><ul><li>Public and private sector </li></ul></ul><ul><ul><li>Medicine availability, affordability, quality, access, and use </li></ul></ul><ul><li>Applied research to address key questions </li></ul><ul><li>Use of data for policy-making and advocacy </li></ul><ul><li>Share experiences </li></ul>
    4. 4. MeTA Toolbox <ul><li>Protocols and methods to assess and explore key aspects of pharmaceutical system </li></ul><ul><ul><li>Build on existing tools where they exist </li></ul></ul><ul><ul><li>Develop new tools to address key gaps </li></ul></ul><ul><li>Core tools to gain basic understanding of pharmaceutical sector in pilot countries in relation to MeTA objectives </li></ul><ul><li>Additional tools to guide priority processes identified by stakeholder groups </li></ul><ul><li>Tools to be available on MeTA website </li></ul><ul><li>Technical support in implementation </li></ul>
    5. 5. Role of Early Data Gathering <ul><li>Encourage use of core tools in pilot countries </li></ul><ul><ul><li>Compile and synthesize existing information </li></ul></ul><ul><ul><li>Roster and summary of publicly available data </li></ul></ul><ul><ul><li>Community access to medicines </li></ul></ul><ul><ul><li>Foundation of country information portal </li></ul></ul><ul><li>Data for priority setting </li></ul><ul><ul><li>Review by MeTA Stakeholder Group </li></ul></ul><ul><ul><li>Systematic consideration of sector-wide issues </li></ul></ul><ul><ul><li>Identify priority activities and future research </li></ul></ul><ul><li>Early data against which to measure progress </li></ul>
    6. 6. Core Tool: Pharmaceutical Sector Scan <ul><li>Objective: To summarize key pharmaceutical sector data for review by stakeholder group in order to identify priorities </li></ul><ul><li>Many existing tools and databases </li></ul><ul><li>Existing pharmaceutical sector data </li></ul><ul><ul><li>Structures and processes </li></ul></ul><ul><ul><li>Legislation and regulation </li></ul></ul><ul><ul><li>Financing and expenditure </li></ul></ul><ul><ul><li>Market statistics </li></ul></ul><ul><ul><li>Therapeutic frameworks (e.g., essential medicines lists) </li></ul></ul><ul><li>Tools and templates to assemble data for review by MeTA stakeholder group </li></ul>04/06/09 MeTA
    7. 7. Core Tool: Review of Data Availability <ul><li>Objective: To summarize the public availability and use of key types of pharmaceutical data </li></ul><ul><li>Key for understanding progress in transparency agenda during MeTA pilot phase </li></ul><ul><li>Focus areas for disclosure </li></ul><ul><ul><li>Registration status and quality </li></ul></ul><ul><ul><li>Availability and price </li></ul></ul><ul><ul><li>Policies on promotion </li></ul></ul><ul><li>Tool to be developed in collaboration with MeTA pilot countries </li></ul>
    8. 8. Core Tool: Stakeholder Process <ul><li>Objective: To describe nature and processes of stakeholder engagement </li></ul><ul><li>Key for understanding progress in accountability agenda during MeTA pilot phase </li></ul><ul><li>Focus areas </li></ul><ul><ul><li>Stakeholder mapping </li></ul></ul><ul><ul><li>Review of stakeholder process and activities </li></ul></ul><ul><li>Tool to be developed in collaboration with MeTA pilot countries </li></ul>
    9. 9. Core Tools: Community Access to Medicines <ul><li>WHO/HAI Pricing Survey </li></ul><ul><li>To gather price data where unavailable </li></ul><ul><li>Launched WHA 2003 </li></ul><ul><li>Measures </li></ul><ul><ul><li>Availability </li></ul></ul><ul><ul><li>Price & affordability </li></ul></ul><ul><ul><li>Price components </li></ul></ul><ul><li>50+ surveys to date </li></ul><ul><li>Methods refined in 2007 </li></ul><ul><li>WHO Monitoring Survey </li></ul><ul><li>Facility survey </li></ul><ul><ul><li>Price, availability, affordability </li></ul></ul><ul><ul><li>Treatment appropriateness </li></ul></ul><ul><ul><li>35+ surveys to date </li></ul></ul><ul><ul><li>Revised in 2007 </li></ul></ul><ul><li>Household survey </li></ul><ul><ul><li>Expenditures, access </li></ul></ul><ul><ul><li>Availability, affordability </li></ul></ul><ul><ul><li>Attitudes </li></ul></ul><ul><ul><li>Field-tested in 3 countries </li></ul></ul>Integrated MeTA survey being tested in Philippines, Ghana, Uganda
    10. 10. Status of Community Data Collection Planned June 2008 April 2004, monitoring 2007 June 2002, February 2005 May 2002, Sept 2005 February 2005 May 2004 May 2002, October 2004, monitoring 2007 WHO-HAI pricing survey World Bank (TBD) MeTA in process WHO 2006 Zambia WHO-MeTA May 2008 pre-2004, WHO-MeTA May 2008 Uganda WHO-MeTA May 2008 pre-2004, WHO-MeTA May 2008 Philippines World Bank planned Peru USAID July 2007 MeTA in process WHO pre-2004 Kyrgyzstan World Bank planned Jordan WHO-MeTA May 2008 WHO in process WHO-MeTA May 2008 Ghana Household survey Price components WHO health facility survey
    11. 11. Additional MeTA Tools: Existing, Planned, or Possible <ul><li>Price components analysis (WHO-HAI) </li></ul><ul><li>Price monitoring (HAI, others using routine data) </li></ul><ul><li>Supply chain mapping (WHO, MIT-Zaragosa) </li></ul><ul><li>Good Governance for Medicines review (WHO) </li></ul><ul><li>Political mapping policy review (Harvard) </li></ul><ul><li>Public procurement performance analysis </li></ul><ul><li>Communication and media mapping and review </li></ul><ul><li>Assessment of quality of promotional materials & practices </li></ul><ul><li>Others? </li></ul>
    12. 12. Technical Assistance <ul><li>Available to pilot countries through several channels </li></ul><ul><ul><li>MeTA Secretariat </li></ul></ul><ul><ul><li>WHO </li></ul></ul><ul><ul><li>World Bank </li></ul></ul><ul><li>International and national consultants </li></ul><ul><li>Country to country collaborations </li></ul>